17 results about "Adoptive immunity" patented technology

The invention relates to an inducible chimeric co-stimulatory receptor (CCR) comprising an intracellular T cell activation dependent localization domain. The invention further relates to an immune cell expressing the inducible CCR, a nucleic acid molecule encoding said inducible CCR, and to a pharmaceutical composition, comprising said immune cell or said nucleic acid molecule. The invention further relates to a method of producing said immune cell and to a method of treating a malignancy, comprising providing immune cells expressing the inducible CCR to a patient in need thereof.

The invention relates to the technical field of biotechnology and immunotherapy, and discloses a method for inducing and amplifying pMHC specific homologous TSCM, which comprises the following steps: a) preparing pMHC presenting a single antigen peptide; b) sorting lymphocytes and mononuclear cells from a donor, and connecting the pMHC presenting the single antigen peptide obtained in the step a) to the surface of the separated mononuclear cells as stimulating cells; c) co-culturing the sorted lymphocytes serving as effector cells and stimulated cells in a culture medium containing a glycogen synthase kinase-3beta inhibitor, and inducing to generate pMHC specific homogeneous TSCM; and d) separating the pMHC specific homologous TSCM obtained in the step c). The method can induce and amplify sufficient pMHC specific homogeneous TSCM for adoptive immunotherapy, overcomes self tolerance and avoids or alleviates GVHD (Growth Vitamin Horse Disease); the preparation method is simple, induction and amplification efficiency is high, and universality and flexibility are achieved.

The present invention relates to the field of adoptive immune cell therapy, in particular adoptive T cell therapy. The present invention provides a conversion receptor which is capable of effectively converting an immunosuppressive signal of TGF [beta], which is normally present in the hostile tumor environment of a solid tumor, into a co-stimulatory signal, thereby improving T cell activation, and which can be safely used in therapy. Also provided are nucleic acids encoding the transforming receptors, cells expressing the receptors and pharmaceutical compositions comprising the cells, in particular for the treatment of cancer or infectious diseases, such as adoptive T cell therapy by solid tumors.

The application belongs to the technical field of biotechnology, and particularly relates to a staged precise regulation in vitro expansion culture method of high-activity gamma delta T cells. In the synergistic activation stage, the complex activator containing zoledronic acid, IL-2, IL-15, IL-12 and IL-21 is used to significantly improve the early activation level of the gamma delta T cells; in the dynamic expansion stage, the concentration of metformin is adjusted step by step to support the continuous and efficient proliferation of the cells; in the gradient maturation stage, the combination system of N-acetyl cysteine, TWS119 and DL-alpha tocopheryl acetate is introduced to help maintain the functional activity and antioxidant state of the cells in the later culture stage. The gamma delta T cells with a purity higher than 90% and an expansion multiple more than 100 times can be obtained by using the method to culture for 10 days, and the cells exhibit significant killing activity to tumor cells, are suitable for the adoptive immunotherapy of tumor and infectious diseases, and have good clinical application prospects.

A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

The present invention relates to the technical field of biomedicine, and specifically relates to immune cells targeting EpCAM and a medical use thereof. Provided is a use of immune cells in the preparation of a drug for preventing or treating a tumor; the immune cells are cells for adoptive immune cell therapy, which can target and kill EpCAM-expressing cells; and the tumor expresses EpCAM and is a metastatic tumor.

To provide methods and compositions for immunotherapy employing a modified T cell or NK cell comprising a receptor that binds to newly identified tumor antigens that can be administered to patients for disease (e.g., cancer) treatment.SOLUTION: The present invention provides a chimeric antigen receptor (CAR) protein, which binds to a specific antigen. For example, a CAR protein binding to FLDETLRSLA (SEQ ID NO: 2) and a CAR protein binding to YNPIRTTF (SEQ ID NO: 3) are illustrated.SELECTED DRAWING: Figure 6B

The application provides a high-efficiency expansion culture method of umbilical cord blood gamma delta T cells and application thereof, and belongs to the technical field of biological medicine. Through a specific two-stage strategy of "initial induction culture + expansion culture", the application is simple in operation, stable in system, and high in success rate, effectively overcomes the defects of limited autologous blood source, unstable expansion and low cell activity in the prior art, and lays a foundation for large-scale preparation and allogeneic application of gamma delta T cells. The umbilical cord blood gamma delta T cells obtained by the method of the application are excellent in quantity, purity, activity and anti-tumor function, and have stronger tumor cell killing ability, and are especially suitable for adoptive immunotherapy. The application breaks through the technical bottleneck of the traditional culture system, provides a high-efficiency, stable and clinically convertible gamma delta T cell expansion scheme, and has important application prospect and market value.

The present invention is directed to humanized CD37-CAR comprising humanized CD37 scFv of the present invention. The present invention is also directed to a bispecific CD19-humanized CD37 CAR, comprising: (i) CD19 VL, (ii) Humanized CD37 ScFv, (iii) CD19 VH, (iv) a transmembrane domain, (v) at least one co-stimulatory domains, and (vi) an activating domain. The CARs of the present invention are useful in the field of adoptive immunity gene therapy for hematological cancers.

The invention relates to the field of biological medicines, in particular to a TCR55 mutant and application thereof.The TCR55 mutant comprises an alpha chain and a beta chain, the TCR55 mutant is obtained after mutation is conducted on the basis of wild TCR55, and the alpha chain of the TCR55 mutant is a mutant obtained after any one of the following sites on the alpha chain of the wild TCR55 is mutated into histidine, the fourth position D and / or the fifth position E of the CDR2 alpha, and the seventh position A of the CDR3 alpha; or the beta chain of the TCR55 mutant is a mutant obtained by mutating any one of the following on the beta chain of the wild type TCR55 into histidine: the second site N of CDR1beta, the second site A of CDR2beta, the fourth site E and / or the sixth site T of CDR2beta, and the thirteenth site Y of CDR3beta. The mutant can be used for identifying HIV (Pol448-456) / HLA-B35, has high activating power, triggers downstream signal transduction, and can be used for transforming T cells to form specific high-activating-power TCR-T cells for T cell adoptive immunotherapy.

Provided herein are methods for preparing and characterizing SARS-cov2 antigen specific immune cell cultures and preparations and methods of using the same in adoptive immunotherapy for cancer, infections, and immune disorders. Also provided are compositions and methods for generating immune calls expressing synthetic antigen binding receptors targeting SARS-cov2 and methods of use of these cells for the treatment and prevention of COVID-19. Also provided are compositions and methods for determining immune response to SARS-cov2 in a subject, detecting SARS-cov2, measuring cytotoxicity induced by SARS-cov2, and detecting the expression and cytotoxicity of synthetic antigen binding receptors targeting SARS-cov2.

This invention relates to the short-chain fatty acid pentanoate and its use as enhancer for cellular immune therapy and anti-tumor therapy. The present invention specifically relates to the metabolite pentanoate and its use in the production of antigen-specific or genetically engineered immune cells. The invention also relates to pharmaceutical compositions comprising such immune cells, as well as their uses in cellular immune therapy (adoptive immune therapy), in particular to an improvement in the treatment of cancer, infectious diseases and immune cell-mediated diseases by means of cellular immune therapy.

The invention provides a micro-environment dynamic regulation and control bioreactor for large-scale culture of immune cells. The micro-environment dynamic regulation and control bioreactor comprises a culture cavity, a temperature control assembly, a gas-liquid exchange assembly, a monitoring assembly and a PLC (Programmable Logic Controller), a sterile sampling port and an inoculation port are formed in the top of the culture cavity, a discharge port is formed in the bottom of the culture cavity, a bottom pipeline of the culture cavity is connected with a waste liquid collecting tank, and a microcarrier matrix and a stirring assembly are arranged in the culture cavity; the micro-environment dynamic regulation and control bioreactor further comprises a nutrition supply assembly. The micro-environment dynamic regulation and control bioreactor for the large-scale culture of the immune cells can dynamically regulate and control the culture micro-environment; meanwhile, a microenvironment dynamic regulation and control technology is matched, accurate matching of nutrition supply and microenvironment parameters is achieved, the NK / CIK cell in-vitro amplification multiple can be larger than or equal to 1000, the cell activity maintenance rate within 14 days is larger than or equal to 90%, the method can be used for tumor adoptive immunotherapy and large-scale production of immune cell preparations, and technical support is provided for industrialization of immune cell therapy products.

The present invention relates to isolated antibody fragments and more in particular single-domain antibodies that have affinity for tumor antigens and tumor-associated antigens such as HER2. Also provided herein is a pharmaceutical composition comprising the antibody fragment, the CAR immune cell comprising said fragment, or the nucleic acid or vector encoding said antibody fragment for use in the prevention and / or treatment of a tumor or cancer, or for use in adoptive immunotherapy such as CAR-T-cell therapy or targeted radiotherapy.

The present disclosure relates generally to compositions and methods for improving the safety of adoptive immune cell therapy, including the use of a depletion tag (e.g., an epitope or a mimotope) that is capable of binding to another molecule (e.g., an antibody) to facilitate the depletion of the engineered immune cells. One class of depletion tags disclosed herein contain an epitope or mimotope derived from a biomarker of a hematologic cancer (e.g., CCR4). A second class of depletion tags disclosed herein contain an epitope or mimotope derived from the same antigen that the engineered receptor binds to (e.g., a DLL3 derived depletion tag for engineered immune cells that bind to DLL3).

To provide compositions and methods for immune cell modulation.SOLUTION: In one aspect, a composition comprises a population or subpopulation of immune cells, and one or more modulating agents selected from the group consisting of specific compounds. The one or more modulating agents (a) improve therapeutic potential of immune cells for adoptive cell therapy; (b) improve cell expansion, maintenance, and / or differentiation properties of immune cells; (c) improve cell proliferation, cytotoxicity, persistence, cytokine response and secretion, and / or cell recall responses of immune cells; and / or (d) increase the number or ratio of a desired immune cell subpopulation.SELECTED DRAWING: Figure 1A

Novel adoptive immunotherapy compositions comprising co-cultured lentiviral vector-transduced autologous antigen presentation cells and T cells are provided herein as well as are methods of use of same in a patient-specific combination immunotherapy that can be used to treat cancers and other diseases and conditions.